Illumina
ILMN
$278.17
+5.14%
Illumina Inc. is a life sciences tools company that provides instruments, consumables, and services for analyzing genetic material, generating over 90% of its revenue from DNA sequencing platforms used in research, clinical diagnostics, oncology screening, and agricultural genomics. The company is the dominant global player in next-generation sequencing (NGS), holding an effective near-monopoly in high-throughput short-read sequencing and functioning as the foundational infrastructure layer for much of the genomics ecosystem, including liquid biopsy and cancer detection players such as Grail. The current investor narrative has shifted decisively from a multi-year turnaround and restructuring story into a momentum-driven re-rating: shares have roughly tripled over the past year, management has raised guidance, and analysts have begun upgrading the name (UBS moved to Buy from Neutral in September 2026), while debate now centers on whether the stock's explosive run has outrun fundamentals and whether competition, China exposure, and the lingering Grail overhang pose risks. Recent commentary, including Zacks' late-August note, captures the tension well: strong fundamentals and raised guidance are acknowledged, but the magnitude of the rally has prompted caution about chasing the stock without a pullback.…
ILMN
Illumina
$278.17
Related headlines
Investment Opinion: Should I buy ILMN Today?
Based on the synthesis of data, the recommendation is Hold. The core thesis is that Illumina's dominant NGS franchise and re-accelerating revenue growth are offset by an overextended stock price that has run ahead of analyst targets, with the average target of $233.55 implying -16% downside. The consensus rating is Buy (mean 2.43), but the price target math suggests caution, and the risk/reward is balanced at current levels.
Supporting evidence includes: 1) Revenue growth of 9.65% YoY in Q2 2026, showing re-acceleration; 2) Strong profitability with a 17.9% net margin and 66.4% gross margin; 3) Free cash flow of $939 million TTM, providing financial flexibility; 4) The P/S ratio of 4.81x is near the low end of its historical range, suggesting the valuation is not stretched on sales. However, the forward P/E of 45.5x is a premium to the sector, and the stock's 188% one-year gain has created technical overextension.
The biggest risks that could invalidate the thesis are: 1) A revenue growth deceleration below 5%, which would pressure the multiple; 2) Margin compression from competitive threats; 3) A broader market downturn given the high beta of 1.416. The rating would upgrade to Buy if the stock pulls back to the $230-$250 range (aligning with analyst targets) or if Q3 earnings show accelerating growth and margin expansion. It would downgrade to Sell if revenue growth falls below 5% or if operating margins drop below 18%. Relative to its history and peers, the stock appears overvalued on forward earnings but fairly valued on sales, leading to a Hold verdict.
Sign up to view all
ILMN 12-Month Price Forecast
Illumina presents a balanced risk/reward at current levels. The company's dominant NGS franchise and re-accelerating revenue growth are compelling, but the stock's 188% one-year rally has pushed it above the average analyst target, suggesting limited near-term upside. The forward P/E of 45.5x prices in an optimistic earnings recovery, leaving little room for error. I would upgrade to bullish if the stock pulls back to the $230-$250 range or if Q3 earnings show accelerating growth and margin expansion. I would downgrade to bearish if revenue growth decelerates below 5% or if competitive pressures intensify, eroding Illumina's market share.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $233.55 and implied upside of -16.0% versus the current price.
Average Target
$233.55
0 analysts
Implied Upside
-16.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$113 - $365
Analyst target range
Illumina is covered by 20 analysts, and the consensus recommendation is Buy with a recommendation mean of 2.43 (on a scale where lower is more bullish), reflecting a moderately constructive but not unanimous view. The average price target is $233.55, which implies roughly -16% downside from the current price of $278.17 — a notable disconnect that suggests the stock has run ahead of where the sell-side models fair value, or that targets have not yet been updated to reflect the recent surge. The consensus leans bullish on fundamentals but the price target math signals caution: with the stock up 188% over a year and 35.7% in the past month, analysts' average target now sits below the market price, a classic sign of a momentum-driven re-rating that has outpaced fundamental revisions. The target range is exceptionally wide, from a low of $113.00 to a high of $365.00 — a spread of $252, or more than 2x the low target — which signals very high uncertainty and divergent views on Illumina's trajectory. The high target of $365 implies roughly +31% upside and likely assumes successful execution on the sequencing growth story, margin expansion toward the high end of historical ranges, multiple expansion on normalized earnings, and resolution of competitive and Grail-related overhangs. The low target of $113 implies roughly -59% downside and likely prices in margin compression, competitive share loss, a recession-driven slowdown in research and clinical spending, or renewed concerns about the balance sheet. Institutional ratings show a recent pattern of upgrades and reaffirmations: UBS upgraded to Buy from Neutral on 2026-09-09, while Piper Sandler (Overweight), Leerink (Outperform), RBC (Outperform), Stifel (Buy), and JP Morgan (Overweight) have all maintained bullish ratings through late September 2026; however, Citigroup remains at Sell and Canaccord at Hold, illustrating the genuine two-sided debate. The wide target dispersion combined with the recent upgrades suggests analyst conviction is strengthening but remains fragmented, and the fact that the average target sits below the current price is a caution flag for momentum-chasing investors.
Bulls vs Bears: ILMN Investment Factors
The bull case for Illumina rests on its dominant NGS franchise, re-accelerating revenue growth, strong profitability, and a historically low P/S ratio that suggests room for multiple expansion. However, the bear case is equally compelling: the stock has tripled in a year, trades at a premium forward P/E of 45.5x, and the average analyst target sits 16% below the current price, indicating the rally may have outrun fundamentals. The most important tension is whether the recent revenue re-acceleration and margin expansion can justify the elevated valuation, or whether the stock is due for a mean-reversion pullback. Currently, the bear evidence appears slightly stronger due to the overextended technicals and the negative implied upside to analyst targets, but the bull case could regain dominance if Q3 earnings beat and guidance is raised again.
Bullish
- Revenue re-acceleration: Q2 2026 revenue grew 9.65% YoY to $1.159 billion, following Q1 2026 revenue of $1.091 billion, indicating a stabilizing and re-accelerating top line after a difficult 2024. The sequential improvement and raised guidance suggest the core sequencing consumables model is compounding again.
- Dominant NGS franchise: Illumina holds a near-monopoly in high-throughput short-read sequencing, generating over 90% of revenue from sequencing instruments, consumables, and services. This entrenched position creates high switching costs and a recurring revenue stream that underpins long-term growth.
- Strong profitability and cash flow: Q2 2026 net income was $207 million with a 17.9% net margin, gross margin of 66.4%, and operating margin of 21.1%. Trailing free cash flow is $939 million, yielding a 4.5% FCF yield on a $20.8 billion market cap, funding buybacks and tuck-in acquisitions.
- Analyst upgrades and bullish consensus: The consensus recommendation is Buy (mean 2.43) from 20 analysts, with recent upgrades including UBS to Buy from Neutral on 2026-09-09. Piper Sandler, Leerink, RBC, Stifel, and JP Morgan maintain bullish ratings, reflecting growing institutional conviction.
Bearish
- Average target implies downside: The average analyst price target of $233.55 implies roughly -16% downside from the current price of $278.17. This disconnect signals that the stock has run ahead of fundamental revisions, a classic sign of a momentum-driven re-rating.
- Extreme overextension and volatility: The stock is up 188.4% over one year and 35.7% in the past month, with a beta of 1.416 indicating 42% more volatility than the market. The maximum drawdown of -25.66% shows sharp pullbacks are possible even within an uptrend.
- Elevated forward valuation: The forward P/E of 45.5x is well above the long-run average and represents a premium to the medical diagnostics sector. This multiple prices in an optimistic earnings recovery to $8.95 per share, leaving little room for disappointment.
- Wide analyst dispersion: The target range spans from $113 to $365, a spread of $252 or more than 2x the low target. This extreme dispersion reflects high uncertainty and divergent views on Illumina's trajectory, with Citigroup at Sell and Canaccord at Hold.
ILMN Technical Analysis
Illumina is in a powerful, sustained uptrend that has carried the stock from a 52-week low of $88.00 to a 52-week high of $309.35, with the current price of $278.17 sitting at roughly 86% of that 52-week range. The 1-year price change of +188.4% massively outpaces the S&P 500's +16.0% over the same period, producing a relative strength reading of +172.4 percentage points — one of the most extreme outperformance spreads in large-cap healthcare. This positioning near the upper end of the range signals strong momentum but also raises the risk of overextension, particularly given the stock's beta of 1.416, which implies roughly 42% more volatility than the broader market and argues for disciplined position sizing. Recent momentum has been equally forceful: the stock is up 35.7% over the past month and 46.3% over three months, with a 6-month gain of 130.0% and a year-to-date advance of 107.0%. The 1-month relative strength versus SPY stands at +33.6 percentage points, confirming that near-term momentum is accelerating rather than decelerating, and the most recent session alone saw a +5.14% move on volume of roughly 1.89 million shares. This acceleration on top of an already steep 1-year trend suggests a momentum regime that can persist but is vulnerable to sharp mean-reversion episodes, especially with a short ratio of 5.52 days indicating a meaningful short base that could amplify moves in either direction. Key technical levels are well defined: the 52-week high at $309.35 is the immediate resistance, and a decisive breakout above it would likely reinforce the momentum narrative and invite trend-following capital, while the 52-week low at $88.00 represents the deep support zone — though intermediate support likely sits near the $250-$265 area where the stock consolidated in late September and early October. The maximum drawdown of -25.66% over the period shows the stock is capable of sharp pullbacks even within its uptrend, and with beta at 1.416, investors should expect drawdowns roughly 1.4x the market's in risk-off environments; a breakdown below the recent consolidation shelf would signal that the momentum trade is unwinding, whereas holding above it keeps the primary uptrend intact.
Beta
1.42
1.42x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$309
Price range past year
Annual Return
+188.4%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +35.7% | +1.9% |
| 3m | +46.3% | +3.9% |
| 6m | +130.0% | +12.1% |
| 1y | +188.4% | +19.2% |
| ytd | +107.0% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Illumina's revenue trajectory is re-accelerating: Q2 2026 (period ending 2026-06-28) revenue came in at $1.159 billion, up 9.65% year-over-year, following Q1 2026 revenue of $1.091 billion and Q4 2025 revenue of $1.160 billion. The sequential and year-over-year pattern shows a business that has stabilized after a difficult 2024 and is now growing in the high-single-digit range, with the sequencing segment contributing $1.054 billion and microarrays $105 million in the most recent period — sequencing remains the overwhelming growth engine at roughly 91% of segment revenue. This re-acceleration, combined with raised guidance noted in recent coverage, supports the bull case that Illumina's core consumables-driven model is compounding again, though the growth rate remains well below the hypergrowth era and leaves the stock reliant on margin expansion and multiple re-rating for further upside. Profitability is robust and improving: Q2 2026 net income was $207 million on a 17.9% net margin, with gross margin at 66.4% and operating margin at 21.1%, while Q1 2026 delivered $134 million of net income at a 12.3% net margin. The sequential margin improvement from Q1 to Q2 reflects operating leverage, with gross profit rising to $770 million from $721 million and operating income climbing to $245 million from $209 million, even as R&D stayed elevated at $252 million. Compared to the prior-year Q2 2025, when net income was $235 million, the current quarter's $207 million is lower on a GAAP basis, but the prior year benefited from non-operating items; the underlying operating margin trajectory (21.1% in Q2 2026 vs. 21.0% in Q2 2025) is stable-to-improving, and the 66.7% gross margin is consistent with the high-margin consumables mix typical of life science tools leaders. The balance sheet is solid but not fortress-like: debt-to-equity stands at 0.94, the current ratio is 2.08, and trailing free cash flow is $939 million, which against a market cap of roughly $20.8 billion implies a free cash flow yield of about 4.5%. ROE is a strong 31.2%, though this is flattered by the company's equity multiplier and by the low equity base following prior write-downs; ROA of 8.7% is more modest. Quarterly free cash flow has been consistent — $161 million in Q2 2026, $251 million in Q1 2026, $267 million in Q4 2025 — and the company holds $1.04 billion in cash, giving it ample liquidity to fund operations, buybacks ($242 million repurchased in Q2 2026), and tuck-in acquisitions without external financing, though the debt load and the historical Grail-related cash drain remain considerations.
Quarterly Revenue
$1.2B
2026-06
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
66.4%
Latest Quarter
Free Cash Flow
$939000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Because Illumina is profitable — Q2 2026 net income of $207 million and trailing EPS of $0.041 — the primary valuation metric is the P/E ratio, which stands at 24.5x trailing and 45.5x forward. The wide gap between trailing (24.5x) and forward (45.5x) P/E is unusual and reflects the fact that trailing EPS is depressed by non-recurring items and a very low TTM earnings base, while forward estimates of $8.95 per share imply the market expects a dramatic earnings recovery; the forward multiple of 45.5x is the more economically meaningful figure and signals that investors are paying a premium for expected earnings normalization and growth. On a price-to-sales basis, the stock trades at 4.81x TTM sales and 9.19x EV/Sales, with EV/EBITDA at 15.1x — multiples that are elevated relative to Illumina's historical norms but not extreme for a franchise life-science tools leader with 66.7% gross margins and a re-accelerating top line. Relative to the broader medical diagnostics and research sector, Illumina's 45.5x forward P/E and 9.2x EV/Sales represent a clear premium, though the company's dominant NGS position, 31.2% ROE, and 66.7% gross margin justify a quality premium; the spread versus the sector is meaningful but defensible if growth sustains in the high-single digits and margins expand. The stock's own historical ratios tell a striking story: P/S has ranged from roughly 12x to 50x over the past several years, and the current 4.81x TTM P/S (or 9.19x EV/Sales) sits near the low end of that historical band, even as the share price has tripled — a paradox explained by the collapse and subsequent recovery of the revenue and earnings base. On P/E, the trailing 24.5x is mid-range versus historical readings that swung from negative to over 100x, while the forward 45.5x is above the long-run average, suggesting the market is pricing in optimistic earnings recovery; the PEG ratio of -0.14 is not meaningful given the distorted trailing earnings base, and investors should focus on the forward earnings trajectory rather than trailing multiples.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~130x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Illumina center on its debt burden and dependence on continued growth to justify valuation. The debt-to-equity ratio of 0.94 is moderate but not fortress-like, and the current ratio of 2.08 provides adequate liquidity. However, the forward P/E of 45.5x assumes earnings recovery to $8.95 per share, and any shortfall in that trajectory could trigger a sharp de-rating. Additionally, the company's revenue is heavily concentrated in sequencing (over 90% of revenue), leaving it vulnerable to competitive disruption or pricing pressure in that core market. The historical Grail-related cash drain and ongoing R&D expenses ($252 million in Q2 2026) further strain resources, though free cash flow of $939 million TTM provides a cushion.
Market and competitive risks are significant given Illumina's premium valuation and high beta. The stock trades at 9.19x EV/Sales and 45.5x forward earnings, well above sector averages, making it susceptible to multiple compression if growth slows or interest rates remain elevated. Beta of 1.416 means the stock is 42% more volatile than the market, amplifying drawdowns in risk-off environments. Competitive threats from emerging NGS players and potential share loss in China, where geopolitical tensions persist, could erode Illumina's dominant position. Recent news highlights the Grail overhang, with Grail's failed NHS trial and FDA catalyst uncertainty adding to the risk profile, even as Illumina's core business remains strong.
The worst-case scenario for Illumina would involve a combination of slowing revenue growth, margin compression, and a broader market sell-off. If revenue growth decelerates below 5% and operating margins contract due to competition, the stock could retest its 52-week low of $88.00, representing a -68% decline from the current price of $278.17. The analyst low target of $113 implies a -59% downside, reflecting a scenario where earnings recovery stalls and the multiple compresses. A breakdown below the $250-$265 consolidation support could accelerate selling, especially with a short ratio of 5.52 days indicating a meaningful short base that could amplify downward moves. In this adverse scenario, investors could lose 60% or more from current levels.
FAQ
The key risks include: 1) Valuation risk: the forward P/E of 45.5x leaves little room for disappointment, and any slowdown could trigger a sharp de-rating; 2) Competitive risk: emerging NGS players and potential share loss in China could pressure growth and margins; 3) Macro risk: with a beta of 1.416, the stock is highly sensitive to market downturns; 4) Company-specific risk: the Grail overhang and integration challenges could distract management and drain resources. These risks are ranked from highest to lowest severity, with valuation and competition being the most immediate threats.
The 12-month forecast is based on three scenarios: bull case (25% probability) targeting $309-$365, base case (50% probability) targeting $233-$278, and bear case (25% probability) targeting $88-$113. The base case is most likely, assuming revenue growth remains in the 8-10% range and operating margins stay near 21%. The key assumption is that the company continues to execute on its growth strategy without major competitive disruptions. However, the wide target range reflects high uncertainty, and investors should be prepared for volatility.
ILMN appears overvalued on forward earnings, with a forward P/E of 45.5x that is well above the sector average and its own historical norms. However, on a price-to-sales basis, the stock trades at 4.81x TTM sales, which is near the low end of its historical range of 12x to 50x, suggesting the market may be undervaluing the revenue base. The discrepancy arises because trailing earnings are depressed, and the market is pricing in a significant earnings recovery. Overall, the stock is fairly valued to slightly overvalued, with the forward multiple implying high expectations for growth.
At the current price of $278.17, ILMN is not an attractive buy due to the stock's extreme overextension and the negative implied upside to the average analyst target of $233.55. The risk/reward is skewed to the downside in the near term, with the stock up 188% over one year and trading at a premium forward P/E of 45.5x. However, for long-term investors willing to tolerate volatility, a pullback to the $230-$250 range would offer a more compelling entry point. The company's dominant NGS franchise and strong cash flow generation make it a quality holding, but patience is warranted.
ILMN is more suitable for long-term investment, given its dominant market position, recurring revenue model, and the secular growth of genomics. The stock does not pay a dividend and has a beta of 1.416, making it volatile and less ideal for short-term trading unless one is a momentum trader. Earnings visibility is moderate, with analyst estimates for EPS of $8.95 in the forward year. A suggested minimum holding period is 2-3 years to ride out volatility and benefit from the long-term growth trajectory. Short-term traders should be cautious of sharp mean-reversion episodes.